RNA Interference Silences the Human Papillomavirus 6b/11 Early Gene E7 in Vitro and in Vivo.

X. Z. Chen,K. J. Zhu,Y. Xu,X. Y. Tang,X. Z. Cai,X. Zhang,H. Cheng
DOI: https://doi.org/10.1111/j.1365-2230.2009.03624.x
2009-01-01
Clinical and Experimental Dermatology
Abstract:Background. RNA interference (RNAi) is a potential therapeutic tool in the treatment of various diseases, such as cancers and viral infections. Silencing of E7 genes is an effective method to suppress human papilloma virus (HPV)-related tumours.Aim. To determine the therapeutic potential of RNAi in controlling condyloma acuminatum (CA).Methods. Small interfering (si) RNA duplexes or small-hairpin (sh) RNA-expressing plasmids targeting the E7 genes of HPV-6b or HPV-11 were inoculated into cultured E7-expressing cells via cationic liposomes, or into E7 gene-expressing mouse tumour models intratumorally or intravenously. Experiments were performed in triplicate and E7 mRNA level was analysed by real-time PCR.Results. The in vitro experiments found that both siRNAs and shRNA-expressing plasmids reduced the mRNA levels of HPV-6b or HPV-11 E7 to 20-40% at the optimum dosage of 25-50 nmol L for siRNAs and 0.1-0.2 mu g/mL for shRNA-expressing vectors. The optimum time for this to happen was 72 h. E7 mRNA expression in tumour models was reduced to 45-50% after three intratumural injections. Intratumoral injections of RNAi effectors induced greater inhibition than did intravenous injections.Conclusions. We conclude that HPV-6b 11 E7 gene expression can be specifically modulated by RNAi, which may provide a useful method in the management of CA.
What problem does this paper attempt to address?